CerRx focuses on the discovery and development of anticancer drugs, with a particular emphasis on ceramides, which are essential components of cell membranes and signaling molecules. Their flagship product is an intravenous emulsion formulation of fenretinide, a synthetic molecule that increases ceramide levels and kills cancer cells. CerRx also plans to conduct Phase II studies of fenretinide with the National Cancer Institute. In addition, they are exploring the development of a glucosylceramide synthase inhibitor called PPMP, which enhances the activity of fenretinide and another ceramide modulator called safingol. The company was founded in 2008 and is based in Lubbock, Texas.